Study of HJB647 for heart failure with reduced pumping ability
Part of Heart & circulation clinical trials.
This trial tests a new medicine, HJB647, in people with heart failure who have a weak heart pump. It aims to see if the drug is safe and well-tolerated. You may qualify if your heart's pumping ability is reduced and you are on a specific standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have mild to moderate heart failure symptoms (NYHA class II or III)
- Your heart's ejection fraction is less than 50%
- Your NT-proBNP level is high (>=600 if normal rhythm, >=900 if atrial fibrillation)
- You have been taking sacubitril/valsartan (at least 49/51 mg twice daily) for at least 4 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational medicine called CRD-4730 (taken as a pill) to see if it can improve heart function and symptoms in people with heart failure and a reduced pumping ability. It may help you feel better and slow the progression of your condition.
This study tests an investigational medicine called EDG-15400 for people with a type of heart failure where the heart muscle is stiff and doesn't relax properly, even though the pumping function is normal. The goal is to see if the medicine improves symptoms and daily functioning.
This study tests an experimental medicine called NNC0537-1482 for people with heart failure. It aims to see if the medicine helps improve symptoms and heart function.
This study tests an experimental drug called LY3971297 to see if it can help people with chronic heart failure. It aims to find out if the drug is safe and if it improves heart function.
This trial tests an investigational drug for people with a type of heart failure where the heart pumps normally but is stiff. The goal is to see if the drug can improve symptoms and quality of life.
This trial tests an investigational drug called CK-4021586 for people with heart failure with preserved ejection fraction (HFpEF). It aims to see if the drug is safe and well-tolerated. You may qualify if you are 40 to 85, have heart failure symptoms, and have a heart that pumps well but shows signs of strain.
Hear when a new Heart Failure With Reduced Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.